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benzene-1-sulfonamide, is a selective mixed endothelin A 
and B receptor antagonist used in the treatment of pulmonary 
hypertension. Elevated endothelin concentrations are strongly 
correlated with the disease severity [2]. Bosentan decreases 
both pulmonary and systemic vascular resistance resulting in 
an increased cardiac output without increasing the heart rate. 
It is indicated for the treatment of pulmonary arterial hyper-
tension (PAH) to improve exercise capacity and symptoms in 
patients with WHO functional class III. Some improvements 
have also been shown in patients with PAH WHO functional 
class II [3]. The drug is also indicated to reduce a number 
of new digital ulcers in patients with systemic sclerosis and 
ongoing digital ulcer disease [3–5].
Bosentan monohydrate can be obtained by the method 
described in the patent WO2014104904 A1 [6] shown in 
Scheme 1. In the first synthesis stage an intermediate com-
pound—4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-
[2,2′-bipyrimidin-]-4-yl) benzenesulfonamide (BO-3) 
was obtained from the starting materials: 4,6-dichloro-5-
(2-methoxyphenoxy)-2,2′-bipyridine (BO-1) and 4-(tert-
butyl) benzenesulfonamide (BO-2). Bosentan monohydrate 
(BO-0) was obtained from BO-3 in the second synthesis 
stage. This two-step synthesis is also known as the first-
generation process consisting of two consecutive replace-
ments of chlorine atoms that exist in the starting dichloro-
pirimidine: the first by tert-butylbenzenesulfonamide and 
the second by ethylene glycol. The method is accompanied 
Abstract Bosentan monohydrate (4-tert-butyl-N-[6-(2-
hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl) 
pyrimidin-4-yl]benzene-1-sulfonamide monohydrate) is a 
dual endothelin receptor antagonist (ERA) applied in the 
treatment of pulmonary arterial hypertension. To achieve 
effective process control of the bosentan monohydrate 
synthesis, it was necessary to develop a selective and not 
highly time-consuming method for ultra-high performance 
liquid chromatography (UHPLC). The method is charac-
terized by adequate sensitivity, reproducibility and selec-
tivity for the determination of bosentan monohydrate and 
related compounds from all synthetic stages. The UHPLC 
separation was carried out by reversed phase chromatogra-
phy on the Acquity BEH C18 column (100 mm × 2.1 mm, 
1.7 µm) with a mobile phase composed of solvent A 
(0.1 %, v/v, acetic acid in water) and solvent B (metha-
nol), in the gradient mode at the flow rate of 0.4 mL min−1. 
Limits of detection and quantification for the compounds 
were ≤0.1 µg mL−1 and 0.3 µg mL−1, respectively. The 
linearity for all related compounds was investigated as in 
the range for the active pharmaceutical ingredient (API) 
and as in the range for the in-process control. The devel-
oped method was validated according to the current guide-
lines, proving the suitability of the method for its intended 
purpose.
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by the formation of two known undesired by-products: 
“deshydroxybosentan impurity” (impurity D) and “dimer 
impurity” (impurity E). Literature suggested [7] that major 
improvement in the reduction of these impurity levels can 
be achieved by means of three consecutive crystalisations 
(two from methanol:isopropyl acetate and one from 
ethanol:water); however, no additional data were revealed. 
Therefore, it is necessary to find an analytical method 
suitable not only to monitor the reaction and levels of the 
obtained by-products, but also the levels of these impurities 
Scheme 1  Bosentan monohy-
drate synthesis
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in the samples from any purification method employed to 
improve the chemical purity of the product.
The majority of analytical papers focus on the deter-
mination of bosentan monohydrate and its metabolites in 
human and animal plasma [8–13]. Some references deal 
with the analysis of bosentan monohydrate in drug formu-
lations [14–18]. There are also a few papers referring to 
the determination of the impurities in the active pharma-
ceutical ingredients (API) of bosentan monohydrate and 
compounds generated during the degradation study [1, 19, 
20]. Some papers deal with the analysis of the in-process 
control (IPC) of the API [21, 22]; however, there is no 
uniform requirement to follow the guidelines for the IPC 
methods.
There are only a few publications describing spectro-
photometric methods for the estimation of bosentan mono-
hydrate in pharmaceutical dosage forms [15–17]. The 
majority of analytical papers concern HPLC with UV and 
MS detection as the techniques used for the separation and 
determination of bosentan, its metabolites and degrada-
tion products [8–14, 18–22]. The analytical procedure was 
published in the authorized USP Pending Monograph and 
in the United States Pharmacopeia Convention. It recom-
mends applying HPLC UV for the determination of bosen-
tan monohydrate and related substances [20, 21].
The aim of this study was to develop a selective UHPLC 
UV method for the determination of the compounds of 
the bosentan monohydrate synthesis. Time of analysis (in 
literature) is about 40–55 min and the method is too time-
consuming for the in-process control of the reaction which 
takes 4 h. What is more, some of the methods reported in 
literature are not sufficiently selective. The main goal of 
this study was to develop a selective and not highly time-
consuming method for ultra-high performance liquid chro-
matography for the determination of the starting materials, 
intermediates and product of the bosentan monohydrate 
synthesis. One method for all the synthesis stages allowed 
to control the impurities at different levels and to find their 
sources. The method was validated and forced degrada-
tion studies were performed in accordance with the Inter-
national Conference on Harmonization (ICH) guidelines 
to prove the specificity and suitability of the developed 
method [24].
Experimental
Reagents and Reference Standards
The working standards of bosentan monohydrate, interme-
diate and impurities D and E were produced in Pharmaceu-
tical Research Institute (Warsaw, Poland). The structure 
of the compounds was confirmed by 1H NMR, 13C NMR, 
API-MS and elementary analysis. The standards potency 
was established on the basis of the organic impurities 
determination (UHPLC UV), residual solvents determina-
tion (GC FID), measurement of water content (Karl Fisher 
method) and determination of sulphated ash. The starting 
materials BO-1 and BO-2 were purchased from Credimate 
Trading Limited (Shanghai, China) and Atomax Chemicals 
Co (ShenZhen, China), respectively. Methanol of HPLC 
super gradient, acetic acid (≥99.5 %) and dimethyl sulfox-
ide (≥99.7 %) were purchased from POCh S.A (Gliwice, 
Poland). Demineralized water (≥18.0 Ω cm−1) from Barn-
stead system (USA) was used. The water solution of ace-
tic acid was freshly prepared and filtered through a nylon, 
0.22 µm pore size membrane (Bellefonte, PA, USA).
Instrumentation
The Dionex UHPLC system (Thermo Scientific, Sunny-
vale, CA, USA) was equipped with a DAD 3000 RS detec-
tor, an LPG 3400 quaternary pomp, a WSP 3000 TRS 
autosampler, a 100 µL syringe, a degasser and a column 
oven. Chromeleon 7.0 software was used for data record-
ing and processing. The chromatographic separation was 
performed using the Acquity BEH C18 column 130 Å, 
100 mm × 2.1 mm × 1.7 µm (Waters, Ireland). The col-
umn and the samples were thermostated at 30 and 25 °C, 
respectively. Separation was achieved using the mobile 
phase consisting of eluent A (0.1 %, v/v, acetic acid in 
water) and eluent B (methanol super gradient grade) with 
the flow rate of 0.4 mL min−1. The analysis was carried 
out under gradient conditions such as time (min)/A (v/v), 
B (v/v); T0.01/70:30, T1.0/40:60, T7.0/40:60, T7.1/5:95, 
T11.5/5:95, T11.6/70:30 and T14.0/70:30. The injection vol-
ume was 3 μL, and DMSO:MeOH (1:9) was used as the 
injection washing solution.
The detector working in the scan mode from 200 to 
400 nm was used for the analysis of the forced degradation 
samples. The detector wavelength was set at 220 nm for the 
determination of related compounds in the bosentan mono-
hydrate samples and at 270 nm for the assay determination.
Preparation of the Sample and Standard Solutions
Stock solutions of bosentan monohydrate and related 
compounds (BO-1, BO-2, BO-3 and impurity D) were 
prepared in methanol at the concentration of 1 mg mL−1. 
The stock solution of impurity E that is sparingly soluble 
in methanol was prepared in chloroform and diluted with 
methanol (CHCl3:MeOH, 2:3, v/v) at the concentration of 
1 mg mL−1. The stock solution of bosentan spiked with 
BO-1, BO-2, impurity D and impurity E at 10.0 µg mL−1 
(1.0 % concentration level) was used as the system suit-
ability solution for the in–process control (SSS1). The stock 
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solution of bosentan monohydrate spiked with all the impu-
rities at 1.5 µg mL−1 (0.15 % concentration level) was used 
as the second system suitability solution (SSS2). The refer-
ence solution was prepared by diluting bosentan monohy-
drate to 1 µg mL−1 (0.10 % concentration level).
Preparation of the In‑Process Control Samples
In-process control solutions were prepared in two stages. 
A small quantity of the sample was taken from the reac-
tion mixture and diluted with methanol to reach the con-
centration of 5 mg mL−1—solution I. The concentration 
was calculated for a product prepared with 100 % reaction 
yield. An appropriate volume of solution I was diluted to 
1 mg mL−1 concentration with methanol—solution II. 
Solution II was filtered through a nylon 0.22 µm pore size 
membrane.
Preparation of the Forced Degradation Studies
Stress testing was performed based on the ICH guidelines 
and available literature data [25–28]. The working stand-
ard of bosentan monohydrate was subjected to various 
forced degradation conditions to check the specificity and 
stability of the sample. Solutions of bosentan monohydrate 
at 10 mg mL−1 were prepared in stressing media in order 
to check its stability in different hydrolysis conditions. 
The solutions of bosentan monohydrate were refluxed with 
2 M HCl (24 h), H2O (24 h), 1 M NaOH (8 h). Bosen-
tan monohydrate was also oxidized using 30 % H2O2 at 
room temperature for 24 h. Photostability was checked by 
exposing to UV radiation using a SUNTEST CPS + light 
cabinet (Heraeus, Germany) at 300-800 nm (ID65 stand-
ard) radiation in two types of vials—glass and quartz. 
The sample in the glass container was stressed for 14 h 
(20160 kJ m−2) and the sample in the quartz container 
for 4 h (5760 kJ m−2). Test was carried out according to 
the ICH Q1B guideline in 25 ± 1 °C and 80 ± 2 % rela-
tive humidity for 24 h. Temperature stability of a bosentan 
monohydrate sample was checked by drying the sample 
at 60 and 100 °C for 24 h. Then the degradation sam-
ples were cooled down to room temperature, diluted to 
1 mg mL−1 with diluents and mixed. For each condition 
a blank solution was prepared in the same manner as the 
stressed sample of bosentan monohydrate by mixing the 
stressing medium with diluents. Bosentan monohydrate 
before degradation was used as the control sample. The 
samples were withdrawn and filtered using PTFE 0.22 µm 
syringe filters (Chromafil, Germany) and analyzed by 
UHPLC UV.
Results and Discussion
UHPLC UV Method Development and Optimization
It was necessary to develop a UHPLC UV method to effi-
ciently control the reaction. To be used for efficient process 
control, the developed method should serve to separate all 
impurities in a short time. For this reason, a short column 
with small particle size was considered. The required selec-
tivity and short method time were achieved on the Acquity 
BEH C18 column (100 mm × 2.1 mm × 1.7 µm). The 
column showed similar efficiency working with the flow 
rates between 0.2 and 0.5 mL min−1. Finally, because of 
the system limitations, the flow rate of 0.4 mL min−1 was 
selected. Bosentan monohydrate was found to exhibit 
two UV absorption maxima at approximately 220 and 
270 nm. The 220 nm wavelength was selected for further 
method development of related substances determination in 
bosentan monohydrate while the 270 nm wavelength was 
selected for the assay determination method. The best peak 
symmetry and resolution were obtained for water with the 
addition of 0.1 %, v/v, acetic acid as mobile phase A. Meth-
anol and acetonitrile were tested as organic mobile phase 
B. Methanol increased the intensity of the peaks, allowing 
to obtain a better signal-to-noise ratio and increased resolu-
tion between bosentan and impurity D. The high sensitiv-
ity of the method allowed for the determination of impu-
rities at low concentrations. Gradient elution was used in 
the method to separate all related compounds. The required 
resolutions and symmetry for BO-1 and BO-2 as well as 
degradation products were achieved using gradient elution 
from 30 to 60 % of methanol. Because of the unsatisfac-
tory resolution between impurity D and bosentan in gradi-
ent elution, isocratic elution was used from the first 2 min 
of the analysis. In the final step of the analysis, the share 
of the organic phase was increased to elute BO-3, impu-
rity E and other degradation products. The chromatogram 
of the developed method is shown in Fig. 1. The solutions 
of bosentan and all impurities were stable at room tempera-
ture. It was not necessary to cool down the samples. The 
temperatures of the autosampler and the column were 25 
and 30 °C, respectively. Temperature above 30 °C caused 
an increase in the resolution between BO-1 and BO-2, but 
at the same time decreased the resolution between impu-
rity D and bosentan. The resolution between bosentan and 
impurity D and the RSD of the compounds area were cho-
sen as critical parameters of the method. The method for 
the determination of the bosentan monohydrate and related 
compounds content was validated in accordance with the 
ICH guidelines [29, 30].
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Method Validation
Documents published by the International Conference 
on Harmonization (ICH) provide a framework for the 
method validation of the impurity assay in a drug sub-
stance and the assay of a drug substance, but there is 
no formal requirement to follow the guidelines for the 
method for the IPC assay [23, 24]. Control the starting 
materials purity requires a limited validation consisting 
of selectivity and LOD. The presented method for the 
assay control of the impurities in an API was validated 
in accordance with the ICH and consists of the selectivity 
and system suitability test, stability of the solutions, limit 
of detecton (LOD) and limit of quantification (LOQ), lin-
earity in the range from the LOQ to 120 % of the con-
centration level, accuracy, precision and robustness. 
Bosentan was validated at the same levels as other known 
impurities to allow to calculate the assay of unknown 
impurities. The assay of unknown impurities was calcu-
lated in relation to bosentan. Moreover, the validation 
was extended by the elements of selectivity and system 
suitability test, LOQ for the starting materials and linear-
ity range for the correct control of the synthesis process. 
The method was validated using the standard solution 
of bosentan monohydrate, starting materials (BO-1 and 
BO-2), intermediate product (BO-3) and impurities D, E, 
standard solutions.
Selectivity and System Suitability Test
The selectivity and system suitability test (SST) of the 
method were determined separately for each stage (start-
ing materials, in-process control and API chemical purity). 
Parameters such as repeatability (RSD of retention time 
and area), resolution and symmetry factors were deter-
mined and compared with the specification of the method. 
The resolution factors Rs must be higher than 1.5 for all 
pairs of peaks. For the starting materials, the selectivity and 
SST were examined with using BO-1 and BO-2 standard 
solutions (SSBO-1 and SSBO-2). The resolution between the 
peaks of BO-1 and BO-2 and their impurities was higher 
than acceptance criteria. The lowest resolution between 
BO-1 and its impurity with RRT 0.93 was 3.4. For BO-2 
and its impurity with RRT 0.88 the lowest resolution was 
6.1. The method was selective for the determination of the 
chemical purity of the starting materials. The results for 
the starting materials are presented in Table 1. For the in-
process control, the selectivity and SST were examined 
using a system suitability solution (SSS1). In the chromato-
gram of the SSS1, the resolution between peaks of bosentan 
and impurity D was the lowest and was equal 2.5, so the 
method was selective for the in-process control. The results 
are collected in Table 1. The selectivity and SST of the API 
chemical purity method was examined using system suit-
ability solutions (SSS2). The results obtained during the 
Fig. 1  UHPLC UV chromatograms of the blank (1), system suitability solution (2)
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system suitability test for the SSS2 proved that bosentan 
and its potential impurities could easily be separated from 
each other and the method was selective for the determina-
tion of the chemical purity in the API samples. The results 
are presented in Table 2.
Selectivity tests proved that the symmetry factors for all 
peaks were in the range of 0.8 ≤ AS ≤ 1.5.
Precision expressed as repeatability was calculated 
for the retention time and peak area and the RSD (rela-
tive standard deviation) was ≤3 % for the peaks under the 
0.5 % concentration level. Moreover, the selectivity and 
SST of the API chemical purity method were examined 
using stress testing.
Degradation of bosentan monohydrate was carried 
out under acidic, alkaline, neutral, oxidative, thermolytic, 
photolytic and hygroscopic stress conditions. Studies of 
peak purity and assessment of mass balance for all the 
stressed samples showed the selectivity of the method. 
The peak match expresses similarity of the spectrum in the 
peak maximum and the spectra on the leading and trailing 
edges. Ideally, the spectra between the peak start and the 
peak end correspond to 100 % of the spectrum in the peak 
maximum, i.e., the peak match value is 1000. The match 
values showed no co-elution of the impurities and bosentan 
monohydrate. The resolution between the peaks was satis-
factory and the mass balance values confirmed the valida-
tion acceptance criteria. The drug remained stable against 
photodegradation, hygroscopic and thermal degradation 
and oxidative hydrolysis. The main product of the degrada-
tion studies was impurity D. In neutral hydrolysis the assay 
Table 1  Results of validation method for substrates samples and in-process control
a Parameters of selectivity: resolution (RS) and symmetry factor (AS)
b Critical value of the Student t test: t(α = 0.95; f = n − 2)
c Parameter for unknown impurities were obtained for Bosentan
d 1-imputiry of BO-1, Relative Retention Time—RRT = 0.75, 2-imputiry of BO-1, RRT = 0.93, 3-imputiry of BO-1, RRT = 1.35, 4-imputiry 
of BO-2, RRT = 0.88, 5-imputiry of BO-2, RRT = 1.35
Parameters Acceptance criteria Purity of substrates
BO-1 BO-2
1d 2d BO-1 3d 4d BO-2 5d
Selectivitya
 Rs ≥1.5 – 10.2 3.4 13.1 – 6.1 15.3




<<0.5, 0.05 – – 0.1, 0.01 – – 0.1, 0.01 –
Parameters Acceptance criteria In-process control
BO-2 BO-1 BO-3 Impurity D Impurity E Bosentanc
Selectivitya
 Rs ≥1.5 8.9 18.0 4.8 2.5 11.7 –
 As 0.8–1.5 1.2 1.3 1.2 1.3 1.4 1.0
Range [%] 0.03–20 0.03–20 0.5–40 0.03–1.5 0.03–1.5 0.03–1.5
Linearity
 Slope 2.9331 2.4050 2.9971 3.1291 3.3795 3.0952
 Standard deviation of 
slope
0.0101 0.0053 0.0241 0.0195 0.0066 0.0045
 Intercept 0.0048 –0.0031 0.5659 0.0057 0.0090 –0.0005
 Standard deviation of 
intercept
0.0830 0.0427 0.4085 0.0126 0.0039 0.0030
 Correlation coefficient >0.998 1.000 1.000 1.000 1.000 1.000 1.000
 Standard deviation 0.2201 0.1223 0.8525 0.0269 0.0087 0.0066
  tbcr – 2.20 2.18 2.31 2.31 2.26 2.31
  ta
b ta > tcr 290.64 450.56 124.41 160.60 510.87 693.85
  tb
b tb < tcr 0.06 0.07 1.39 0.46 2.32 0.16
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of impurity D had increased twice. Significant degradation 
was observed in acidic hydrolysis (2 M HCl, 8 h, reflux). 
Bosentan was most degraded in alkaline hydrolysis (1 M 
NaOH, 8 h, reflux). The results are presented in Table 3.
Stability of the Solutions
A stability test was carried out on standard solutions 
(SSBO-1 and SSBO-2), system suitability solution (SSS1, 
Table 3  Results of forced degradation studies for bosentan monohydrate
Degradation conditions Main peak 
purity




RRT Peak area ≥0.03 %
Alkaline hydrolysis
 (1M NaOH, 8 h, reflux)
OK 0.64 0.09 9.90 90.17 100.07
0.72 0.45
0.94 (Impurity D) 9.12
1.08 (BO-3) 0.04
1.15 (Impurity E) 0.15
Acidic hydrolysis
 (2M HCl, 8 h, reflux)
OK 0.40 0.23 1.64 99.74 101.38
0.45 0.10
0.54 0.07
0.94 (Impurity D) 1.07
1.08 (BO-3) 0.05
1.15 (Impurity E) 0.06
Oxidative degradation
 (30 % H2O2, 8 h, RT)
OK 0.94 (Impurity D) 0.05 0.21 100.12 100.33
1.08 (BO-3) 0.03
1.15 (Impurity E) 0.05
Neutral hydrolysis
 (H2O, 24 h, reflux)
OK 0.94 (Impurity D) 0.12 0.34 99.86 100.20
1.08 (BO-3) 0.06
1.15 (Impurity E) 0.07
Photodegradation
 (Light, glass vial, 14 h, 
UV: 20160 kJ/m2)
OK 0.60 0.03 0.35 100.02 100.36
0.95 (Impurity D) 0.11
1.07 (BO-3) 0.05
1.15 (Impurity E) 0.11
Photodegradation
 (Light, quartz vial, 4 h, 
UV: 5760 kJ/m2)
OK 0.95 Impurity D) 0.11 0.33 100.58 100.91
1.07 (BO-3) 0.05
1.15 (Impurity E) 0.11
Photodegradation
 (Light, glass vial in 
aluminum foil, control 
sample)
OK 0.95 (Impurity D) 0.11 0.34 99.89 100.23
1.07 (BO-3) 0.06
1.15 (Impurity E) 0.12
Thermal degradation
 (100 °C, 24 h)
OK 0.95 (Impurity D) 0.12 0.40 95.29 95.69
1.07 (BO-3) 0.06
1.14 0.03
1.15 (Impurity E) 0.12
Hygroscopic degradation
 (25 °C, 80 % RH, 24h)
OK 0.95 (Impurity D) 0.11 0.34 99.66 100.00
1.07 (BO-3) 0.05
1.15 (Impurity E) 0.12
Control sample (not stressed)
235-064-1
AAn/041/12
OK 0.94 (Impurity D) 0.11 0.32 99.91 100.23
1.08 (BO-3) 0.05
1.15 (Impurity E) 0.11
229-182-1
AAn/134/11
OK 0.94 (Impurity D) 0.05 0.18 99.82 -
1.06 (BO-3) 0.04
1.15 (Impurity E) 0.06
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SSS2). The solutions were tested for stability within 24 h. 
Repeatability (retention times and peaks area), resolution 
and a symmetry factor were determined and compared with 
the specification of the method. The obtained results indi-
cated that SSBO-2, SSS1 and SSS2 are stable for 24 h and 
SSBO-1 was stable for 3 h. During this time, no significant 
changes in the profile of the tested solutions were observed.
Linearity
It was checked that the response of the detector is linear to 
the concentration of the analyte for all compounds. No less 
than five calibration standard solutions at different concen-
tration levels (three analysis for each) were prepared and 
analyzed to receive sets of data points. The linearity was 
evaluated by a linear regression analysis to calculate the 
slope, y-intercept, and correlation coefficient (R2). An addi-
tional restriction is that Student t test should be passed.
Linearity for API
The calibration curve for unknown impurities was investi-
gated in the concentration range 0.3–1.2 µg mL−1 (0.03–
0.12 %), calculated in relation to bosentan and from 0.3 to 
0.18 µg mL−1 (0.03–0.18 %) for all known impurities of the 
API (BO-1, BO-2, BO-3, impurity D and impurity E). Five 
solutions were used, each injected three times (n = 15). 
According to the results of the linearity test, the response 
factor for BO-1, BO-2, BO-3, impurity D and impurity E 
was determined. All results are presented in Table 2. All 
criteria were fulfilled.
Response Factors
During the linearity studies, the response factor for every 
related substance was assessed. To assess the response fac-
tors, standards solutions containing the compounds at 3 or 
more different concentrations were prepared and analyzed. 
The response factors were calculated using a method based 
on comparing the slope of each compound’s regression 
line with the slope of bosentan monohydrate’s regression 
line. In the case of impurity E the response factor played 
an important role, because it was above the upper limit of 
1.2—according to pharmacopeia [26]. The factor must be 
used as a correction factor when calculating the concentra-
tion with the use of the bosentan peak area. The response 
factors are presented as average values in Table 2.
Linearity for the In‑Process Control
In order to obtain effective process control, the linearity of 
the API method was checked in an extended range for all 
compounds. The calibration curve was investigated in the 
concentration range 0.3–200 µg mL−1 (0.03–20.0 %) for 
the starting materials (12 solutions for BO-1, n = 36 and 11 
solutions for BO-2, n = 33). In the case of BO-3, the range 
was 0.5–40 % (5–400 µg mL−1) (13 solutions, n = 39). The 
calibration curve for known impurities was investigated in 
the concentration range 0.3–15 µg mL−1 (0.03–1.5 %), 8 
solutions for impurity D, n = 24 and 9 solutions for impu-
rity E, n = 27. The calibration curve for unknown impu-
rities was calculated in relation to bosentan and was also 
extended. The curves for the in-process control were inves-
tigated in the concentration range 0.3–15 µg mL−1 (0.03–
1.5 %), 8 solutions, n = 24. All results are presented in 
Table 1.
Limits of Detection and Quantification
The limits of detection (LOD) and the limit of quantifica-
tion (LOQ) are the same for the in-process control and for 
the API. The LOD and LOQ were estimated as signal-to-
noise ratio. The values of signal-to-noise ratio were calcu-
lated by Chromeleon 7 software. Signal-to-noise ratio for 
the LOD and LOQ must be higher than 3.3 and not lower 
than 10.0, respectively. In accordance with the ICH, the 
reporting threshold should be lower than 0.05 % which 
corresponds to the 0.5 µg mL−1 concentration level for the 
analyzed compounds. The analytical method was sensitive 
enough as the LOQ was well below the reporting thresh-
old. The precision for the LOQ level was below 3.0 %. The 
LOQ and LOD for all compounds were tested on the pre-
pared three solutions at the concentrations levels close to 
the LOQ or LOD. All solutions were injected three times 
(n = 9). The results are shown in Table 2.
Accuracy
There is no formal requirement to check the accuracy for 
the IPC method, so the accuracy studies were performed 
for the method only in the range used for the determination 
of the API purity.
The accuracy of the API method was separately deter-
mined for known related compounds and bosentan mono-
hydrate. Model solutions were prepared at 3 concentration 
levels of the related substance—close to the LOQ, speci-
fication level and 120 % of the specification level, each 
injected three times (n = 27). A solution of bosentan mono-
hydrate standard was used as matrix. The accuracy of the 
method for unknown impurities was determined by analys-
ing the solutions of bosentan monohydrate standard at three 
different concentration levels (LOQ, 100 and 120 % of the 
acceptance level).
The accuracy of the method was investigated as the 
absolute recovery of sample solutions. Recovery studies for 
known compounds were performed using three calculation 
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methods: applying linearity equation (method I), on the 
impurity standard independent point (method II) and on 
the bosentan standard independent point using a response 
factor (method III). The recoveries of unknown impurities 
(calculated on bosentan) were obtained using calculation 
methods I and II. Table 2 provides validation data results.
Precision
The precision of the method for the API was studied for 
repeatability and intermediate precision. Differences 
between the results were tested by the RSD and statistical 
Horrat’s test.
The precision of the analytical procedure was tested by 
preparing 6 individual model solutions, analyzed in tripli-
cate, n = 18. The RSD for all analyses was calculated for 
each impurity peak area. For the investigation of unknown 
impurities, sample solutions of bosentan monohydrate were 
prepared by diluting the stock solutions to their specifica-
tion limit. Intermediate precision was carried out by two 
analysts using different instruments on different days. The 
results are presented in Table 2.
Robustness
The robustness of the method is the ability to remain unaf-
fected by small variations in the method parameters. The 
method robustness was evaluated by varying method 
parameters such as the percentage of the organic solvent 
(±2 %), percentage of acid in the mobile phase (0.05 
and 0.15 %), column temperature (±3 °C) and flow rate 
(±0.01 ml/min), as well as wavelength (±2 nm). Method 
parameters were evaluated by changing one factor at a 
time. Changes in the chromatographic conditions slightly 
influenced the chromatographic parameters of the analysis. 
The resolution factors Rs were higher than 1.5 for all pairs 
of peaks. The symmetry factor As remained in the accept-
ance range for all compounds. The obtained results proved 
that the selectivity of the analysis did not change signifi-
cantly under different conditions.
In‑Process Control
The presented method allowed to control intermediate 
compounds and impurities at different levels for all syn-
thesis stages. The analysis of the substrate samples proved 
the absence of impurities which could lower the reaction 
yield. It was necessary to determine a UHPLC UV method 
to efficiently control the reaction. The results of the optimi-
zation of the synthesis process described in the patent WO 
2014104904 A1. Short analysis time, selectivity and sensi-
tivity of the method allowed for accurate monitoring of the 
reaction and changes in the level of impurities.
Conclusions
The developed method for the in-process control of the 
bosentan monohydrate synthesis has significant advan-
tages over other methods proposed in literature and official 
pharmacopoeial documents. The proposed method is short, 
sensitive, specific and selective enough to cope with the 
in-process samples. A wide scope of the in-process control 
allowed to find optimal reaction conditions and a purifica-
tion method that would make the process efficient from 
the manufacturing perspective and help obtain a pharma-
ceutical grade product. Forced degradation studies and the 
extended range of the validation proved the usefulness of 
the developed method for its intended purpose.
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